Vimarsana
Biggest News Aggregation in the World

Jordan Schecter News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jordan Schecter. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jordan Schecter Today - Breaking & Trending Today

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed - Vimarsana News

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

Published: April 23, 2024

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati...

Source: pharmiweb.com
Related Topics:
Region FlamandeEdmond ChanDrug AdministrationEuropean UnionCommittee For Orphan Medicinal ProductsJanssen Cilag InternationalEuropean Medicines AgencyEuropean CommissionArea Lead HaematologyJohnson InnovativeNew England JournalProfessor JesSan MiguelTranslational MedicineUniversidad De NavarraJordan SchecterVice PresidentDisease Area LeaderMultiple MyelomaOrphan Medicinal ProductsProduct CharacteristicsInnovative Medicine
Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy - Vimarsana News

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Published: April 22, 2024

Media contact: Investor contact: ...

Source: marketscreener.com
Related Topics:
United StatesRegion FlamandeEdmond ChanJenni MildonCiltacabtagene AutoleucelEuropean Commission Grants Conditional ApprovalLegend Biotech United States IncJanssen Biotech IncDrug AdministrationAmerican Society Of Clinical OncologyEuropean CommissionJanssen Cilag InternationalChinese Company Legend Biotech To Develop InvestigationalAmerican Cancer SocietyCommittee For Orphan Medicinal ProductsJanssen Research DevelopmentJohnson CompanyEuropean UnionEuropean Medicines AgencyExchange CommissionCilag InternationalArea Lead HaematologyJohnson InnovativeNew England JournalProfessor Jes
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma - Vimarsana News

FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma

Published: April 10, 2024

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Source: pharmacytimes.com
Related Topics:
Binod DhakalJanssen Research DevelopmentDivision Of HematologyJanssen Biotech IncOncologic Drugs Advisory CommitteeCollege Of WisconsinJanssen BiotechPostmodern StudioDrugs Advisory CommitteeStudy ComparingVersus PomalidomideParticipants With RelapsedLenalidomide Refractory Multiple MyelomaJanssen ResearchMedical CollegeJordan SchecterInnovative MedicineTargeted Treatment ApprovedRefractory Multiple Myeloma Who Have ReceivedLeast One Prior LineStandard CareLenalidomide Refractory Multiple
Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study - Vimarsana News

Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

Published: June 5, 2023

News Release Media Contacts: Jessica Castles Smith +1 732-501-8181 Satu Glawe +49 172-294-6264 ... | June 5, 2023

Source: marketscreener.com
Related Topics:
United StatesSatu GlaweBinod DhakalDivision Of HematologyClinical Development Cellular Therapy ProgramEuropean Medicines AgencyJanssen Biotech IncCongress AbstractEuropean CommissionCollege Of WisconsinLegend Biotech United States IncJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of Clinical OncologyJanssen Research DevelopmentDrug AdministrationNews ReleaseReduces RiskDisease ProgressionEarlier Line Multiple Myeloma TreatmentLandmark PhaseNew England JournalJanssen Pharmaceutical CompaniesClinical OncologyAnnual MeetingEuropean Hematology
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma - Vimarsana News

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Published: January 27, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI®...

Source: prnewswire.com
Related Topics:
United StatesHemophagocytic LymphohistiocytosisSatu GlaweClinical Development Cellular Therapy ProgramNational Cancer InstituteJanssen Biotech IncJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonJapan Ministry Of HealthAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesDrug AdministrationEuropean CommissionData Monitoring CommitteeExchange CommissionCompanies Of JohnsonLegend Biotech United States IncIndependent Data MonitoringIndependent Data Monitoring CommitteeJordan SchecterVice PresidentJanssen ResearchJanssen BiotechLegend Biotech United States